Genprex provides positive preclinical update on GPX-002 diabetes gene therapy
Genprex (NASDAQ:GNPX) issued a clinical update on January 7, 2026, for its diabetes gene therapy program, highlighting significant preclinical progress and regulatory advancements for GPX-002.











